Stocktoria
Dianthus Therapeutics, Inc. /DE/ DNTH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Dianthus Therapeutics, Inc. /DE/ financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — |
| R&D expense | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Cash & equivalents | $51.1M | $22.8M | $132.3M | $15.4M | $131.7M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
| Shareholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M |
Source: SEC EDGAR filings · CIK 0001690585 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.